Anchiano Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Jerusalem Israel (2004)
Status: Acquired by ChemomAb Ltd. (2021)

Organization Overview

First Clinical Trial
2006
NCT00393809
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Anchiano | Anchiano Therapeutics Israel Ltd. | BioCancell Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

dta-h19 (2 trials)

inodiftagene vixteplasmid (4 trials)

Drugs in Phase 1 Trials (1)

bacille calmette-guerin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3